These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 10584932

  • 1. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy.
    Todo T, Rabkin SD, Chahlavi A, Martuza RL.
    Hum Gene Ther; 1999 Nov 20; 10(17):2869-78. PubMed ID: 10584932
    [Abstract] [Full Text] [Related]

  • 2. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus.
    Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB, Martuza RL.
    Hum Gene Ther; 1999 Nov 20; 10(17):2741-55. PubMed ID: 10584921
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
    Todo T, Rabkin SD, Martuza RL.
    Cancer Gene Ther; 2000 Jun 20; 7(6):939-46. PubMed ID: 10880026
    [Abstract] [Full Text] [Related]

  • 4. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.
    Cinatl J, Cinatl J, Michaelis M, Kabickova H, Kotchetkov R, Vogel JU, Doerr HW, Klingebiel T, Driever PH.
    Cancer Res; 2003 Apr 01; 63(7):1508-14. PubMed ID: 12670897
    [Abstract] [Full Text] [Related]

  • 5. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T, Martuza RL, Dallman MJ, Rabkin SD.
    Cancer Res; 2001 Jan 01; 61(1):153-61. PubMed ID: 11196154
    [Abstract] [Full Text] [Related]

  • 6. Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.
    Nakano K, Todo T, Zhao G, Yamaguchi K, Kuroki S, Cohen JB, Glorioso JC, Tanaka M.
    J Gene Med; 2005 May 01; 7(5):638-48. PubMed ID: 15754306
    [Abstract] [Full Text] [Related]

  • 7. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.
    Toda M, Rabkin SD, Martuza RL.
    Hum Gene Ther; 1998 Oct 10; 9(15):2177-85. PubMed ID: 9794202
    [Abstract] [Full Text] [Related]

  • 8. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
    Toda M, Iizuka Y, Kawase T, Uyemura K, Kawakami Y.
    Cancer Gene Ther; 2002 Apr 10; 9(4):356-64. PubMed ID: 11960286
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters.
    Nakano K, Todo T, Chijiiwa K, Tanaka M.
    Mol Ther; 2001 Apr 10; 3(4):431-7. PubMed ID: 11319903
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model.
    Mashour GA, Moulding HD, Chahlavi A, Khan GA, Rabkin SD, Martuza RL, Driever PH, Kurtz A.
    Exp Neurol; 2001 May 10; 169(1):64-71. PubMed ID: 11312559
    [Abstract] [Full Text] [Related]

  • 11. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus.
    Todo T, Feigenbaum F, Rabkin SD, Lakeman F, Newsome JT, Johnson PA, Mitchell E, Belliveau D, Ostrove JM, Martuza RL.
    Mol Ther; 2000 Dec 10; 2(6):588-95. PubMed ID: 11124059
    [Abstract] [Full Text] [Related]

  • 12. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity.
    Toda M, Rabkin SD, Kojima H, Martuza RL.
    Hum Gene Ther; 1999 Feb 10; 10(3):385-93. PubMed ID: 10048391
    [Abstract] [Full Text] [Related]

  • 13. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.
    Todo T, Martuza RL, Rabkin SD, Johnson PA.
    Proc Natl Acad Sci U S A; 2001 May 22; 98(11):6396-401. PubMed ID: 11353831
    [Abstract] [Full Text] [Related]

  • 14. Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis.
    Cinatl J, Michaelis M, Driever PH, Cinatl J, Hrabeta J, Suhan T, Doerr HW, Vogel JU.
    Neoplasia; 2004 May 22; 6(6):725-35. PubMed ID: 15720798
    [Abstract] [Full Text] [Related]

  • 15. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.
    Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL.
    Hum Gene Ther; 1999 Sep 01; 10(13):2237-43. PubMed ID: 10498254
    [Abstract] [Full Text] [Related]

  • 16. In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer.
    Endo T, Toda M, Watanabe M, Iizuka Y, Kubota T, Kitajima M, Kawakami Y.
    Cancer Gene Ther; 2002 Feb 01; 9(2):142-8. PubMed ID: 11857031
    [Abstract] [Full Text] [Related]

  • 17. Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer.
    Zager JS, Delman KA, Malhotra S, Ebright MI, Bennett JJ, Kates T, Halterman M, Federoff H, Fong Y.
    Mol Med; 2001 Aug 01; 7(8):561-8. PubMed ID: 11591892
    [Abstract] [Full Text] [Related]

  • 18. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation.
    Blank SV, Rubin SC, Coukos G, Amin KM, Albelda SM, Molnar-Kimber KL.
    Hum Gene Ther; 2002 Mar 20; 13(5):627-39. PubMed ID: 11916486
    [Abstract] [Full Text] [Related]

  • 19. Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207.
    Oyama M, Ohigashi T, Hoshi M, Murai M, Uyemura K, Yazaki T.
    Jpn J Cancer Res; 2000 Dec 20; 91(12):1339-44. PubMed ID: 11123435
    [Abstract] [Full Text] [Related]

  • 20. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer.
    Bennett JJ, Delman KA, Burt BM, Mariotti A, Malhotra S, Zager J, Petrowsky H, Mastorides S, Federoff H, Fong Y.
    Cancer Gene Ther; 2002 Nov 20; 9(11):935-45. PubMed ID: 12386832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.